• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Butitta Cynthia M

    3/18/26 8:01:43 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AUTL alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    BUTITTA CYNTHIA M

    (Last)(First)(Middle)
    C/O AUTOLUS THERAPEUTICS PLC
    THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

    (Street)
    LONDONW12 7FP

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Autolus Therapeutics plc [ AUTL ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    American Depositary Shares (1) (1)Ordinary Shares10,000(1)D
    Share Option (right to buy) (2)03/08/2028American Depositary Shares47,095$8.38D
    Share Option (right to buy) (2)03/28/2029American Depositary Shares25,000$30.24D
    Share Option (right to buy) (2)06/18/2030American Depositary Shares12,500$13.25D
    Share Option (right to buy) (2)06/18/2031American Depositary Shares12,500$7.57D
    Share Option (right to buy) (2)06/28/2032American Depositary Shares20,000$2.84D
    Share Option (right to buy) (2)06/30/2033American Depositary Shares105,000$2.38D
    Share Option (right to buy) (2)06/28/2034American Depositary Shares80,000$3.48D
    Share Option (right to buy) (3)06/26/2035American Depositary Shares80,000$2.32D
    Explanation of Responses:
    1. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
    2. Fully vested and exercisable.
    3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.
    /s/ Cynthia Butitta03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $AUTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUTL

    DatePrice TargetRatingAnalyst
    2/17/2026$9.00Buy
    H.C. Wainwright
    11/18/2024$7.00 → $7.60Neutral → Buy
    Goldman
    11/15/2024$13.00Neutral → Buy
    Redburn Atlantic
    11/9/2023$10.00Buy
    Deutsche Bank
    3/27/2023$8.00Overweight
    Wells Fargo
    3/17/2023$5.00Buy
    Bryan Garnier
    More analyst ratings

    $AUTL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc

    SCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    2/17/26 9:51:49 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc

    SCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    2/13/26 4:07:51 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Autolus Therapeutics plc

    424B3 - Autolus Therapeutics plc (0001730463) (Filer)

    1/26/26 4:09:22 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Piccina Cintia

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:40:01 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Butitta Cynthia M

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:01:43 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Leiderman Elisabeth

    3 - Autolus Therapeutics plc (0001730463) (Issuer)

    3/18/26 8:00:44 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

    LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026. Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN,

    3/16/26 4:10:00 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics to Participate in Upcoming Investor Conferences

    LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. TD Cowen 46th Annual Health Care ConferenceDate and time: March 3, 2028; 11:10am EST / 4:10pm GMTLocation: Boston, MAPresenter: Chief Executive Officer Dr. Christian Itin A webcast of the presentation will be available on the "Events" page in the "Investor Relations & Media" section of the Company's website at https://www.autolus.com/investor-relations-media/events/. A replay

    2/24/26 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

    VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and toward precision biologics like mRNA and oncolytic viruses. The FDA is actively accelerating this cycle, having granted multiple breakthrough designations in January 2026 alone for platforms that demonstrate genuine survival durability[2]. This structural realignment positions Oncolytics Biotech Inc. (NASDAQ:ONCY), Moderna (NASDAQ:MRNA), Immunome (NASDAQ:IMNM), Autolus Therapeutics (NASDAQ:AUTL), and Prelude Therapeutics (NASDAQ:PRLD) within the emerging biological innovation c

    2/5/26 9:26:03 AM ET
    $AUTL
    $IMNM
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AUTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Autolus Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00

    2/17/26 8:13:55 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics upgraded by Goldman with a new price target

    Goldman upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $7.60 from $7.00 previously

    11/18/24 7:38:09 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics upgraded by Redburn Atlantic with a new price target

    Redburn Atlantic upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $13.00

    11/15/24 7:30:20 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 4:32:31 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 1:44:27 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

    11/14/24 9:12:16 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Financials

    Live finance-specific insights

    View All

    Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

    LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026. Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN,

    3/16/26 4:10:00 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

    Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data generation to support market growth and expansion continues; data in severe refractory systemic lupus erythematosus (srSLE) show no ICANS or high-grade CRS, demonstrate achievement of definition of remission in SLE (DORIS) in 83% (n=5/6) of patients and complete renal response (CRR) in 50% (n=3/6) of patientsLeadership team bolstered to support next phase of growth and optimization of business operationsConference call to be held today at 8:30 am EST / 1:30 pm GMT; conference call participants should p

    11/12/25 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

    LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its third quarter 2025 financial results and operational highlights before open of U.S. markets on Wednesday, November 12, 2025. Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are requi

    10/30/25 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUTL
    Leadership Updates

    Live Leadership Updates

    View All

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

    Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from

    4/16/25 1:00:00 AM ET
    $AUTL
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

    LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus' executive team and will lead the company's development organization effective September 30, 2024. "Matthias has a proven track record of success in pharmaceutical product development, achieving many key regulatory milestones and marketing approvals across several cancer indications," said Dr. Christian Itin, Chief Executive Officer of Autolus. "His in-depth development experience and leadership skil

    9/19/24 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care